Impact of Trastuzumab Combined with Chemotherapy on Tumor Markers,Inflammatory Factors and Adverse Reactions in Patients with HER2-positive Metastatic Gastric Cancer
SUN Jianpu
ZHANG Qian
WANG Xuezhi
WANG Meng
LU Xudong
REN Dongfei
Abstract：Objective To investigate the impact of combination of Trastuzumab and chemotherapy on tumor markers,in-flammatory factors and adverse reactions in patients with human epidermal growth factor receptor 2(HER2)-positive metastatic gastric cancer.Methods A total of 120 patients with HER2-positive metastatic gastric cancer were collected from September 2021 to October 2023.According to different treatment regimens,they were divided into chemotherapy group(n=58,conventional chemo-therapy)and monoclonal antibody group(n=62,Trastuzumab combined with chemotherapy).The clinical effect,tumor markers,inflammatory factors and occurrence of adverse reactions were compared between the two groups.Both groups were followed up for 1 year,and the median overall survival time was recorded in the two groups.Results The disease control rate in monoclo-nal antibody group was higher than that in chemotherapy group(P<0.05).After treatment,the levels of serum carcinoembryonic antigen,carbohydrate antigen 19-9,carbohydrate antigen 72-4,monocyte chemoattractant protein-1,interleukin-1β,and C-X-C motif chemokine ligand 10 in the two groups were decreased,and the above levels in monoclonal antibody group were lower than those in chemotherapy group(P<0.05).There were no differences in the incidence rates of adverse reactions such as hematolog-ical toxicity,gastrointestinal reaction,liver-kidney function damage and cardiac toxicity between groups(P>0.05).The median overall survival time was 14.2 months(95%CI:12.8,15.6)in monoclonal antibody group and 11.5 months(95%CI:10.2,12.8)in chemotherapy group(P<0.05).Conclusion Trastuzumab combined with chemotherapy has good effects in the treatment of HER2-positive metastatic gastric cancer.It can effectively reduce the tumor markers,relieve the inflammatory response,and pro-long the survival time in patients with HER2-positive metastatic gastric cancer,with high safety.
Keywords：Stomach neoplasmsHuman epidermal growth factor receptor 2MetastasisTrastuzumabCarbohydrate antigen 19-9Interleukin-1βAdverse reaction
Publication Date：2025-07-13
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 21-25 )